Huapont Life Sciences Co.,Ltd

002004

CNE000001JJ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
4.58 ^CNY	+0.44%		-2.14%	-1.72%

24/05	Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023	CI
26/04	Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023

June 09, 2023 at 01:17 am IST

Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.

Latest news about Huapont Life Sciences Co.,Ltd

Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023	25/05	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023.	02/04	CI
Huapont Life Sciences Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares.	27/12	CI
Huapont Life Sciences Co.,Ltd authorizes a Buyback Plan.	27/12	CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component A Share Index	11/12	CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component Index	11/12	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023	09/23/09	CI
Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022	19/23/19	CI
Huapont Life Sciences Co.,Ltd Proposes Final Cash Dividend for the Year 2022	28/23/28	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
Huapont Life Sciences Forms 100 Million Yuan Drug Research, Information Sharing Center	10/23/10	MT
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/22/18	CI
Huapont Life Sciences Co., Ltd. Announces Dividend on A Shares for the Year 2021, Payable on June 2, 2022	28/22/28	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Huapont Life Sciences Co., Ltd. Approves Profit Distribution for 2021	14/22/14	CI
Huapont Life Sciences Maintains Final 2021 Dividend as Full-Year Profit Rises 2.8%	22/22/22	MT
Huapont Life Sciences Co., Ltd. Proposes Final Cash Dividend for 2021	22/22/22	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	29/21/29	CI

Chart Huapont Life Sciences Co.,Ltd

Duration

Period

More charts

HUAPONT LIFE SCIENCES CO., LTD. is a China-based company principally engaged in the research and development, manufacture and sales of pesticide chemical products. The Company operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The Company is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUAPONT LIFE SCIENCES CO.,LTD	-1.72%	124.99Cr
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+33.05%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.09%	20TCr
ROCHE HOLDING AG	-5.77%	20TCr
AMGEN INC.	+6.19%	16TCr